文献速递糖尿病

使用胰岛素泵的1型糖尿病女性后代先天性畸形:一项前瞻性队列研究

Congenital malformations among offspring of women with type 1 diabetes who use insulin pumps: a prospective cohort study.
PubMed 文献 · Diabetologia · 2023-01-14

该研究为前瞻性多国队列的二次分析,纳入2088例1型糖尿病孕妇,其中胰岛素泵组750例、每日多次胰岛素注射(MDI)组1338例。结果显示,泵组虽在孕早期血糖控制更好,但后代先天性畸形、围产期及新生儿死亡风险与MDI组相比均无显著差异;作者认为需进一步研究孕期泵治疗的有效性与安全性。

要点

  • 泵组与MDI组后代至少一种畸形的比例分别为13.5%和11.2%,粗OR 1.23(95%CI 0.94,1.61),倾向评分匹配后OR 1.11(95%CI 0.81,1.52),无显著差异。
  • 泵组与MDI组严重畸形比例分别为2.8%和3.1%,调整后OR 0.78(95%CI 0.42,1.45),无显著差异。
  • 泵组与MDI组围产期死亡比例分别为1.6%和1.3%,调整后OR 2.02(95%CI 0.69,5.93),无显著差异。

核心结论

  • 胰岛素泵治疗与先天性畸形风险降低无关,尽管与MDI相比孕早期血糖控制更好。
  • 需要进一步研究探讨孕期泵治疗的有效性和安全性。

研究设计与样本

  • 前瞻性多国队列的二次分析,纳入2088例真实世界中的1型糖尿病孕妇,其中胰岛素泵组750例、MDI组1338例。
  • 采用粗数据和倾向评分匹配数据的logistic回归计算后代先天性畸形或围产期/新生儿死亡的OR。

主要发现

  • 入组时(孕周8周;95%CI 4,14),泵组较MDI组大学学历比例更高(37.3% vs 25.1%,p<0.001),平均HbA1c更低(51±10 mmol/mol [6.8±0.9%] vs 54±14 mmol/mol [7.1±1.3%],p<0.001)。
  • 泵组较MDI组HbA1c低于75 mmol/mol(9%)的比例更高(97.6% vs 91.9%,p<0.001),补充叶酸报告率更高(86.3% vs 74.8%,p<0.001)。
  • 至少一种畸形的胎儿比例:泵组13.5% vs MDI组11.2%(粗OR 1.23;95%CI 0.94,1.61;p=0.13;倾向评分匹配调整OR 1.11;95%CI 0.81,1.52;p=0.52)。
  • 至少一种严重畸形的胎儿比例:泵组2.8% vs MDI组3.1%(粗OR 0.89;95%CI 0.52,1.51;p=0.66;调整OR 0.78;95%CI 0.42,1.45;p=0.43)。
  • 一种或多种轻微畸形(无严重畸形)的胎儿比例:泵组10.7% vs MDI组8.1%(粗OR 1.36;95%CI 1.00,1.84;p=0.05;调整OR 1.23;95%CI 0.87,1.75;p=0.25);围产期死亡比例:泵组1.6% vs MDI组1.3%(粗OR 1.23;95%CI 0.57,2.67;p=0.59;调整OR 2.02;95%CI 0.69,5.93;p=0.20);新生儿死亡比例:泵组0.3% vs MDI组0.3%(n=2 vs n=4,p=不适用)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究探讨孕期泵治疗的有效性和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Continuous subcutaneous insulin infusion by insulin pump is often superior in improving glycaemic control compared with conventional multiple daily insulin injection (MDI). However, whether pump treatment leads to improved pregnancy outcomes in terms of congenital malformations and perinatal death remains unknown. The present aim was to evaluate the risk of malformations and perinatal and neonatal death in pregnant women with type 1 diabetes treated with pump or MDI. METHODS: We performed a secondary analysis of a prospective multinational cohort of 2088 pregnant women with type 1 diabetes in a real-world setting who were treated by pump (n=750) or MDI (n=1338). ORs for offspring with congenital malformations or perinatal or neonatal death were calculated using crude data and by logistic regression on propensity score-matched data. RESULTS: At enrolment (gestational week 8; 95% CI 4, 14), pump users had a higher educational level (university degree: 37.3% vs 25.1%; p<0.001) and better glycaemic control (mean HbA1c: 51±10 mmol/mol [6.8±0.9%] vs 54±14 mmol/mol [7.1±1.3%], p<0.001) compared with MDI users. Moreover, a greater proportion of pump users had an HbA1c level below 75 mmol/mol (9%) (97.6% vs 91.9%, p<0.001), and more often reported taking folic acid supplementation (86.3% vs 74.8%; p<0.001) compared with MDI users. All clinically important potential confounders were balanced after propensity score matching, and HbA1c remained lower in pump users. The proportion of fetuses with at least one malformation was 13.5% in pump users vs 11.2% in MDI users (crude OR 1.23; 95% CI 0.94, 1.61; p=0.13; propensity score-matched (adjusted) OR 1.11; 95% CI 0.81, 1.52; p=0.52). The proportion of fetuses with at least one major malformation was 2.8% in pump users vs 3.1% in MDI users (crude OR 0.89; 95% CI 0.52, 1.51; p=0.66; adjusted OR 0.78; 95% CI 0.42, 1.45; p=0.43), and the proportions of fetuses carrying one or more minor malformations (but no major malformations) were 10.7% vs 8.1% (crude OR 1.36; 95% CI 1.00, 1.84; p=0.05; adjusted OR 1.23; 95% CI 0.87, 1.75; p=0.25). The proportions of perinatal and neonatal death were 1.6% vs 1.3% (crude OR 1.23; 95% CI 0.57, 2.67; p=0.59; adjusted OR 2.02; 95% CI 0.69, 5.93; p=0.20) and 0.3% vs 0.3% (n=2 vs n=4, p=not applicable), respectively. CONCLUSIONS/INTERPRETATIONS: Insulin pump treatment was not associated with a lower risk of congenital malformations, despite better glycaemic control in early pregnancy compared with MDI. Further studies exploring the efficacy and safety of pump treatment during pregnancy are needed.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Thorius IH, Husemoen LLN, Nordsborg RB, et al. Congenital malformations among offspring of women with type 1 diabetes who use insulin pumps: a prospective cohort study. Diabetologia. 2023. PMID: 36640191. doi:10.1007/s00125-022-05864-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。